Enabling Technologies to Accelerate Development of Oral Biodevices (R43/R44 Clinical Trial Not Allowed) | PA 19 076

Frequently Asked Questions (FAQs)

What is the NIH funding opportunity PA 19-076?

PA 19-076 is an NIH funding opportunity titled "Enabling Technologies to Accelerate Development of Oral Biodevices (R43/R44 Clinical Trial Not Allowed)." It uses the small business R43/R44 mechanisms (SBIR/STTR-style) to support engineering and technology development that moves intraoral biodevices from early concepts toward practical clinical use.

What is the main goal of this FOA?

The main goal is to fund transformative enabling technologies that solve the technical bottlenecks preventing oral biodevices from being reliably built, optimized, validated, and translated. The focus is on the engineering work needed to reach deployable prototypes and core building blocks that can support later clinical studies and commercialization.

Are clinical trials allowed under this opportunity?

No. The FOA is explicitly "Clinical Trial Not Allowed." The intent is to fund the technology development that makes later clinical trials feasible, but not to run clinical trials under this specific award.

What kinds of devices does NIH mean by "oral biodevices"?

In this opportunity, oral biodevices are technologies designed to operate inside the mouth (intraoral) and provide clinically useful information or therapeutic benefit. They may be new devices or significant improvements to existing devices, with an emphasis on reliable operation in the oral environment.

What types of clinical impact is NIH looking for?

NIH emphasizes applications aligned with precision medicine. That includes devices that may help detect or diagnose disease earlier, guide individualized treatment decisions, monitor response over time, or capture meaningful measures of function and outcomes. While devices operate in the mouth, the intended impact can span both oral health conditions and systemic disease.

Does the FOA focus only on oral health, or can it relate to systemic disease too?

It can relate to both. The FOA recognizes that oral biomarkers and oral-based sensing or therapeutic platforms may be relevant to broader medical care, not just conditions limited to the oral cavity.

What does NIH mean by "enabling technologies" in this context?

Enabling technologies are the practical engineering solutions and core components that make intraoral biodevices feasible and reliable. The FOA is aimed at addressing the messy, high-risk technical details that determine whether a device can be worn or used comfortably and still deliver accurate, repeatable results.

What major technical areas are highlighted for development?

The FOA highlights integrated engineering approaches that can include multifunctional biosensors, oral-cavity-suitable materials and coatings, microfabrication methods, power and communication strategies, biocompatibility and safety engineering, signal processing and analytics, and robust packaging that survives saliva, mechanical forces, temperature variation, and biofouling.

Why is "integration" a central theme of this FOA?

Because intraoral biodevices often require multiple subsystems to work together in a harsh and variable environment. NIH is encouraging applicants to combine electronic, physical, and biological systems into a functional, safe, and effective platform rather than treating each component as an isolated lab demonstration.

What kinds of outputs or deliverables are expected?

The FOA expects tangible proof-of-concept prototypes and key components needed to make them work. Examples include prototype intraoral biodevices, dedicated biosensors for specific oral targets, and core technologies that can serve as building blocks for future devices. It also supports integrated subsystem demonstrations (for example, sensor plus materials plus electronics plus data pipeline) that show a credible path to a safe and effective product for a defined clinical application.

Does the FOA support improving existing devices, or only brand-new devices?

It supports both. Applicants may propose new biodevices or significant improvements to existing ones, as long as the work addresses real technical bottlenecks and advances translation toward practical clinical use.

What makes a project a good fit based on the description provided?

A good fit is a small business-led project focused on engineering and translational problem-solving for intraoral biodevices, producing prototype-level proof of concept and/or reusable core technologies, and showing a credible path toward a safe and effective product without conducting clinical trials under this award.

Why does NIH encourage interdisciplinary teams for this opportunity?

Because intraoral biodevices sit at the intersection of multiple domains. Competitive projects are expected to draw from engineering and sensor development and may also involve pharmacology (for therapeutic or drug-delivery functions), chemistry (assays, biomarker detection, surface chemistry, antifouling), and clinical disciplines like medicine and dentistry to ensure relevance to workflows and endpoints.

Are partnerships between academia and industry encouraged?

Yes. The FOA explicitly encourages partnerships between academia and industry to strengthen translation, manufacturability, and eventual commercialization rather than purely exploratory research.

Who is eligible to apply?

Eligibility is limited to small businesses, consistent with the R43/R44 mechanism described. The opportunity is framed as SBIR/STTR-style support for small business-led technology development.

Are foreign institutions or non-U.S. entities eligible?

No. Foreign institutions and non-U.S. entities are not eligible to apply. Non-domestic components of U.S. organizations are also not eligible.

Can a U.S.-based applicant include any foreign involvement?

Potentially. The synopsis notes that "foreign components" may be allowed in certain cases as defined by NIH policy. This typically means limited foreign involvement may be included if well-justified and compliant with NIH requirements, while the applicant organization remains U.S.-based and eligible.

What is the funding category and assistance listing information provided?

The opportunity is described as an NIH discretionary grant in the health category, with CFDA 93.121 listed in the synopsis.

What was the original closing date mentioned?

The original closing date listed in the provided synopsis was January 5, 2022.

Is there an award ceiling or expected number of awards specified in the synopsis?

No. The synopsis does not specify an award ceiling or the expected number of awards, suggesting award size and volume would depend on NIH budgets, application quality, and program priorities.

What is the practical "bridge" this FOA is trying to fund?

The FOA is trying to bridge the gap between a lab concept and a deployable prototype by funding the engineering work required for reliability, safety, and repeatability in the oral environment (for example, surviving saliva and mechanical forces, addressing biofouling, and ensuring robust sensing and data handling).

Does the FOA require a clearly defined clinical application?

Based on the synopsis, the program supports prototypes and integrated approaches that demonstrate a credible path to a safe and effective product intended for a clearly defined clinical application.

What kinds of use cases are implied for intraoral biodevices in this FOA?

The use cases implied include detecting or diagnosing disease earlier, guiding individualized treatment, monitoring response over time, and capturing meaningful measures of function and outcomes, with relevance to both oral and systemic conditions.